Category Archives: Biotechnology

Biotechnological applications of polar microbes have been identified as a key focus area. Further, as highlighted in a series of tweets by MoES, the proposed centre will be be expected to investigate the relationship between climate change and the emergence of infectious diseases, derive products from nature that could be valuable to the industry, identify compounds for purposes such as preventing infections, and explore novel molecules for commercial use.

The MoES-DBT collaboration will jointly identify more thrust areas over time.

Initially, researchers will file proposals to carry out research using the existing MoES polar stations. However, joint laboratories will be set up in the future so that researchers wont have to move samples to and from laboratories in India to carry out experiments.

We have been doing research in the Arctic, Antarctic, and Himalayas the three poles but unfortunately we have not had expertise in biological sciences. DBT has the expertise, so we want to work together, Dr M Ravichandran, director of the National Centre for Polar and Ocean Research (NCPOR), told Swarajya.

Based in Goa, NCPOR is Indias premier R&D institution responsible for the countrys research activities in the polar and Southern Ocean regions. It is an autonomous body under the Ministry of Earth Sciences, which is the nodal ministry for polar research in India.

The focus of the MoES-DBT joint effort, Dr Ravichandran says, will be bioprospecting and microbiology research.

Bioprospecting is short for biodiversity prospecting. It is the systematic study of bio-resources, like plants and microorganisms, with the purpose of developing commercially valuable products for pharmaceutical, agricultural, and other applications and overall for the benefit of society.

The process of bioprospecting goes over the stages of sample collection, isolation, characterisation, and translation to product development and commercialisation, the United Nations Development Programme notes in its 2016 report on the subject.

Bioprospecting, when properly regulated, generates revenues that can be directly linked to the conservation of biodiversity and to the benefit of local communities, the report says.

With eyes on bioprospecting and other research in biology, India aims to add biotechnology muscle to the science it carries out in the polar region.

We want to encourage polar, cold-climate biotechnology study to strengthen the area of polar research, Dr Ravichandran says.

Research in polar biology has been underway at a small scale in India. The work is done by very few people and usually includes researchers from different universities and institutes whose proposals get accepted by NCPOR.

The Centre for Cellular and Molecular Biology, Wildlife Institute of India, Zoological Survey of India, and Banaras Hindu University are among the institutes that have carried out long-term programmes in areas like microbiology and wildlife ecology at the poles.

Much of the biology research over the last decade has involved the study of bacterial diversity and adaptability in snow and ice, both in terrestrial and marine environments in the region.

However, there is now a sense that India can do more in polar biology.

The regions around the North and South Poles north of the Arctic, or south of the Antarctic Circles, respectively are important natural laboratories for scientific research.

Much of the land and marine expanse within this region still remains unexplored and therein lies the opportunity for researchers to find answers to scientific questions.

Indias engagement with the polar regions goes back a long time. It began with the signing of the Svalbard Treaty in February 1920 to initiate formal ties with the Arctic. Getting started with the Antarctic region took longer, but began eventually when India launched its first Antarctic expedition in 1981.

Now, four decades later, India set off on its 40th scientific expedition to Antarctica in January 2021.

More:
Explained: India To Add Biotechnology Muscle To Its Polar Science Research - Swarajya

The Detailed Market intelligence report on the Global Agricultural Biotechnology Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Global Agricultural Biotechnology Market place for the forecast 2021 2027.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Get Sample Report:@ https://industrystatsreport.com/Request/Sample?ResearchPostId=11569&RequestType=Sample

Scope Of The Report:

Report evaluates the growth rate and the Market value based on Market dynamics, growth inducing factors. The complete knowledge is based on latest industry news, opportunities and trends. The report contains a comprehensive Market analysis and vendor landscape in addition to a SWOT analysis of the key vendors.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Agricultural Biotechnology Market.

Key Benefits for Agricultural Biotechnology Market Reports

Agricultural Biotechnology Market Segmentation:

Segmentation by Type:

PlantsAnimalsMicrobes

Segmentation by Application:

Vaccine DevelopmentTransgenic Crops & AnimalsAntibiotic DevelopmentNutritional SupplementsFlower CulturingBiofuels

By Region

Agricultural Biotechnology Market Key Players:

KWS SAAT SE & Co. KGaAChemChinaCortevaLimagrainMITSUI & CO., LTD.Evogene Ltd.Bayer AGValent BioSciences LLCNufarmMarrone Bio InnovationsPerformance Plants Inc.ADAMA Ltd

Table of Content

1. Chapter Report Methodology1.1. Research Process1.2. Primary Research1.3. Secondary Research1.4. Market Size Estimates1.5. Data Triangulation1.6. Forecast Model1.7. USPs of Report1.8. Report Description

2. Chapter Global Agricultural Biotechnology Market Overview: Qualitative Analysis

2.1. Market Introduction2.2. Executive Summary2.3. Global Agricultural Biotechnology Market Classification2.4. Market Drivers2.5. Market Restraints2.6. Market Opportunity2.7. Agricultural Biotechnology Market: Trends2.8. Porters Five Forces Analysis2.8.1. Bargaining Power of Suppliers2.8.2. Bargaining Power of Consumers2.8.3. Threat of New Entrants2.8.4. Threat of Substitute Product and Services2.8.5. Competitive Rivalry within the Industry2.9. Market Attractiveness Analysis2.9.1. Market Attractiveness Analysis by Segmentation2.9.2. Market Attractiveness Analysis by Region

3. Chapter Global Agricultural Biotechnology Market Overview: Quantitative Analysis

3.1. Global Agricultural Biotechnology Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 20273.2. Global Agricultural Biotechnology Market Revenue Market Share (%), 2014- 20273.3. Global Agricultural Biotechnology Market Sales (Number of Units), Market Share (%) and Growth Rate (%), 2014- 20273.4. Global Agricultural Biotechnology Market Sales Market Share (%), 2014- 2027

4. Chapter Global Agricultural Biotechnology Market Analysis: Segmentation By Type

5. Chapter Global Agricultural Biotechnology Market Analysis: Segmentation By Application

6. Chapter Global Agricultural Biotechnology Market Analysis: By Manufacturer

6.1. Global Agricultural Biotechnology Market Revenue (USD Million), by Manufacturer, 2014 20276.2. Global Agricultural Biotechnology Market Share (%), by Manufacturer, 20186.3. Global Agricultural Biotechnology Market Sales (Number of Units), by Manufacturer, 2014 20276.4. Global Agricultural Biotechnology Market Share (%), by Manufacturer, 20186.5. Global Agricultural Biotechnology Market Price (USD/Unit), by Manufacturer, 2014 20276.6. Global Agricultural Biotechnology Market Revenue Growth Rate (%), by Manufacturer, 2014 20276.7. Merger & Acquisition6.8. Collaborations and Partnership6.9. New Product Launch

7. Chapter Agricultural Biotechnology Market: Regional Analysis

This comprehensive report will provide:

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Get Full Report: @ https://industrystatsreport.com/Agriculture/Premium-Research-On-Agricultural-Biotechnology-Market-Growth/Summary

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com

Read more from the original source:
Agricultural Biotechnology Market Share 2021 Global Trend, Segmentation, Size, Business Growth, Top Key Players Analysis Industry, Opportunities and...

As brands and consumers alike seek out innovation, biotechnology and beauty are increasingly intertwining.

During Beauty Inc @20, Alex Lorestani, chief executive officer and cofounder of Geltor; John Melo, CEO of Amyris, and Barbara Paldus, CEO and founder of Codex Beauty spoke about biotechs impact on beauty with WWDs senior editor Allison Collins.

More from WWD

For Amyris, its lab-produced squalane has become the companys bread and butter. Were about 70 percent of the world market for squalane, and were expanding the market by 25 percent per year, Melo said. Our sales are growing at about 40 percent per year, and were selling squalane to about 3,000 beauty brands around the world.

Geltor, for its part, produces collagen that is identical to human collagen, and it, too, is tracking upticks in interest. Customers and consumers are beginning to understand what you can really get from biology, its becoming more of an opportunity driver, Lorestani said.

Paldus, who came from a professional background in biotechnology, founded Codex Beauty after the birth of her son. I couldnt find preservative systems that werent fossil fuel-based, she said. Thats how we ended up with biotech ingredients; we were looking for ferments that could actually act as a preservative system.

Sustainability was a major theme, too, as lab-grown alternatives can cause less environmental damage than other sourcing methods. We save 3 million sharks a year with squalane were making through fermentation. Sustainability starts with this idea that once you kill the shark, youre not going to produce any more squalene from that shark. Ours we make from sugarcane, which is a five-year crop, Melo said.

The case was the same with Geltor. We had a third-party perform a lifecycle analysis and we could show that it required 79 percent less water, 50 percent less greenhouse gas and requires 40 percent less land to make proteins through fermentation, Lorestani said.

Story continues

The thing with biotechnology today is it can deliver anything across the spectrum, he continued. Theres a really exciting spectrum of products to have and were seeing more and more third-party entities emerge to certify different kinds of products.

Amyris value proposition is two-pronged: not only are ingredients less impactful environmentally, theyre also less expensive, 30 percent less than alternative sources, according to Melo. As we learn about the consumer and the purpose we have for them, theyre all for sustainability. So, it needs to perform as well, or better, then the alternative source, he said. Cost has to be at least the same, or better.

During the Q&A, Paldus said communicating around biotechnology requires a lot of consumer education. Biotechnology is actually natural the proteins and stem cells are 100 percent equivalent to those extracted from plants. Biotech is actually natural 2.0, because youre getting sustainable ingredients that havent been exposed to pollution, she said. These ingredients also often perform better, because theyre undiluted.

FOR MORE FROM WWD.COM, SEE:

Amyris Partners With I Am That Girl

The 11 Best Collagen Powders for Firm, Glowing Skin

The 14 Best Collagen Serums for Enhanced Firmness and Wrinkle Reduction

Sign up for WWD's Newsletter. For the latest news, follow us on Twitter, Facebook, and Instagram.

See the original post here:
Biotechnology Execs Discuss the Industrys Impact on Beauty - Yahoo Lifestyle

Halozyme Therapeutics, Inc. (HALO) is around the middle of the Biotechnology industry according to InvestorsObserver. HALO received an overall rating of 36, which means that it scores higher than 36 percent of all stocks. Halozyme Therapeutics, Inc. also achieved a score of 48 in the Biotechnology industry, putting it above 48 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 36 would rank higher than 36 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $39.53 as of 2:35 PM on Friday, Jun 4, a rise of $0.69, or 1.79% from the previous closing price of $38.84. The stock has traded between $39.10 and $39.78 so far today. Volume today is below average. So far 399,257 shares have traded compared to average volume of 953,640 shares.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

View original post here:
Should You Hold Halozyme Therapeutics, Inc. (HALO) in Biotechnology Industry? - InvestorsObserver

IVERIC bio Inc (ISEE) is around the top of the Biotechnology industry according to InvestorsObserver. ISEE received an overall rating of 72, which means that it scores higher than 72 percent of all stocks. IVERIC bio Inc also achieved a score of 98 in the Biotechnology industry, putting it above 98 percent of Biotechnology stocks. Biotechnology is ranked 107 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

IVERIC bio Inc (ISEE) stock is down -3.8% while the S&P 500 has gained 0.88% as of 2:34 PM on Friday, Jun 4. ISEE is down -$0.26 from the previous closing price of $6.84 on volume of 269,144 shares. Over the past year the S&P 500 has gained 35.90% while ISEE has gained 65.74%. ISEE lost -$1.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on IVERIC bio Inc (ISEE) Stock.

Continued here:
Is IVERIC bio Inc (ISEE) a Leader in the Biotechnology Industry? - InvestorsObserver

A rating of 91 puts Salarius Pharmaceuticals Inc (SLRX) near the top of the Biotechnology industry according to InvestorsObserver. Salarius Pharmaceuticals Inc's score of 91 means it scores higher than 91% of stocks in the industry. Salarius Pharmaceuticals Inc also received an overall rating of 57, putting it above 57% of all stocks. Biotechnology is ranked 109 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Salarius Pharmaceuticals Inc (SLRX) stock is higher by 3.02% while the S&P 500 is lower by -0.91% as of 9:52 AM on Thursday, Jun 3. SLRX is up $0.04 from the previous closing price of $1.33 on volume of 640,392 shares. Over the past year the S&P 500 is up 33.53% while SLRX is up 12.30%. SLRX lost -$0.42 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Salarius Pharmaceuticals Inc (SLRX) Stock.

See the article here:
Where Does Salarius Pharmaceuticals Inc (SLRX) Stock Fall in the Biotechnology Field After It Is Up 12.30% This Week? - InvestorsObserver

SAN FRANCISCO, June 02, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9th at 12:00 pm PT / 3:00 pm ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at http://www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Companys Investors website, in addition to following the Companys press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit http://www.vir.bio.

Original post:
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference - Yahoo Finance

Share your insights and experiences to improve patent prosecution in biotechnology areas at the USPTOs next Biotechnology, Chemical and Pharmaceutical Customer Partnership (BCP) meeting. The meeting will be held virtually.

Register for this event.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders. The partnership works to improve the quality of the agencys products and services. The meeting willdiscuss:

Date and Location:

Day 1: Tuesday, June 15, 2021, 1 - 5p.m. ET; Online

Day 2: Wednesday, June 16, 2021, 12:30 - 5p.m. ET; Online

BCP agenda

The USPTO looks forward to hearing from its customers and does not intend to use this forum to seek or arrive at any consensus.

For questions and comments regarding this event, please email: USPTOBCP1600@USPTO.GOV

See the original post here:
Attend the Biotechnology, Chemical and Pharmaceutical (BCP) Partnership meeting - United States Patent and Trademark Office

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the companys board of directors.

Mike is a highly experienced executive with an established track record of leading financial strategy and execution for a number of life science companies, as well as other industries. His experience will be incredibly valuable to Verve and our evolution toward clinical development, said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. We look forward to leveraging his insights and knowledge of best practices for financial operations at growing biotechnology companies as we continue to advance our pipeline.

Verves targeted approach to addressing the causal drivers of cardiovascular disease through single-course gene editing medicines holds significant promise to transforming treatment for people with this highly prevalent and life-threatening disease, said Mr. MacLean. I have been impressed by the progress the company has been making, led by an exceptional team of individuals, and am pleased to partner with them to help support the continued growth of the company.

Mr. MacLean has more than 30 years of experience in financial leadership roles in the life sciences and other industries. In addition, he has been a key player in strategy and operations for high growth companies. He joined Avidity Biosciences as CFO prior to its IPO in June 2020. Prior to Avidity, he served as CFO of Akcea Therapeutics, Inc., where he led the buildout of Akcea's financial and commercial infrastructure, and was the CFO of PureTech Health, plc. Previously, he led Biogens worldwide finance operations. Earlier in his career, Mr. MacLean was an audit partner at KPMG and Andersen.

About Verve Therapeutics

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The companys initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verves lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patients risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit http://www.VerveTx.com.

More here:
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors - Business Wire

HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural differentiation technology platform company, today announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases.

The partnership leverages Neurophth's experience in global gene/cell therapy drugs development and understanding of ophthalmic diseases to complement Hopstem's expertise in GMP manufacturing and quality assurance of iPSC-derived clinical cell products to provide next-generation ocular treatments. Under the terms of agreement, Hopstem Biotechnology will receive upfront and milestone payments for the development of candidate cell product for agreed retinal degenerative disorder. Neurophth will have the option to license the candidate product and will be responsible for development and commercialization of the licensed product. In addition, Neurophth agreed to license Hopstem's iPSC reprogramming patent and GMP iPSC line with additional payments to Hopstem at different product development stages. According to the agreement, Hopstem will also share part of the product sales.

"This collaboration exemplifies Neurophth's long-term commitment to advancing the field of ophthalmic treatment as we continue to expand and progress our innovative pipeline of ocular candidates," said Bin Li, M.D., Ph.D., Founder and Chairman of Neurophth Therapeutics. "Combining the methods of stem cell technology, induced pluripotent stem cells is a promising technology that can offer an extraordinary potential for regenerative therapy, disease modeling and drug screening."

"We are very excited by this partnership with Neurophth. The human induced pluripotent stem cell (hiPSC) line we developed is made by transforming the skin of a healthy donor into stem cells that are capable of multiplying and becoming any type of cell in the human body, meeting GMP requirements. Thanks to our iPSC-derived clinical cell product manufactory and quality platform developed since 2019, we are able to speed up ocular cell product development with Neurophth, the leading ocular therapy company in the field. Together, our aim is to offer safe and effective regenerative medicine with hiPSC-derived cellsfor reversing the progression of ocular diseases and restoring vision for patients," Jing Fan, Ph.D., Founder and CEO of Hopstem Biotechnology.

"iPSCs holds the promise for treatment of retinal degenerative disorders where AAV-mediated gene therapy is unreachable," said Alvin Luk, Ph.D., M.B.A., CEO at Neurophth. "Hopstem is one of the most respected pioneers in the field of iPSC translational medicine. We are confident that their technology and expertise, combined with Neurophth's deep knowledge in ophthalmology and drug development, has the potential to unlock future generations of gene/cell therapy treatments for patients."

About Neurophth

Neurophth is China's first gene therapy company for ophthalmic diseases. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and US, Neurophth, a fully integrated company, is striving to discover and develop gene therapies for patients suffering from blindness and other eye diseases globally. Our validated AAV platform which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept data with investigational gene therapies in the retina. Our most advanced investigational candidate, NR082 (NFS-01 project, rAAV2-ND4), in development for the treatment ofND4-mediated Leber hereditary optic neuropathy (LHON), has granted orphan designation by theU.S FDA and its IND has also been approved by China NMPA. The pipeline also includesND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic macular edema and wet age-related macular degeneration), and five other preclinical candidates. Neurophth has initiated the scaling up in-house manufacturing process in single-use technologies to support future commercial demand at the Suzhou facility. To learn more about us and our growing pipeline, please visitwww.neurophth.com.

About Hopstem

Hopstem Biotechnology is one of the first few iPSC cell therapy companies in China. The company was founded in January 2017 in Hangzhou (China) and Baltimore (US) by neuroscientists and stem-cell biologists from Johns Hopkins University. Hopstem has established a world-leading neural differentiation platform as well as patented iPSC reprogramming method and high standard GMP manufactory and quality system. The mission of Hopstem is to apply these cutting-edge technologies to develop innovative cell therapies for CNS and other disorders. Our leading clinical product, hNPC01, is a human forebrain neural progenitor cell product for stroke and traumatic brain injuries, etc. Preliminary studies in rat and monkey pMCAO stroke models have suggested that majority of those transplanted hNPCs differentiated into functional neural cells and formed significant new connections with the rat neurons in distal regions. To learn more about us, please visit http://www.hopstem.com.

View original content:http://www.prnewswire.com/news-releases/neurophth-therapeutics-and-hopstem-biotechnology-announce-strategic-partnership-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-the-treatment-of-ocular-diseases-301302715.html

SOURCE Neurophth Therapeutics, Inc.

Read the rest here:
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for...